John M Floberg1, Lingjue Wang2, Nilantha Bandara1, Ramachandran Rashmi1, Cedric Mpoy1, Joel R Garbow3,4, Buck E Rogers1, Gary J Patti2, Julie K Schwarz1,4,5. 1. Department of Radiation Oncology, Washington University, St. Louis, Missouri. 2. Department of Chemistry, Washington University, St. Louis, Missouri. 3. Mallinckrodt Institute of Radiology, Washington University, St. Louis, Missouri. 4. Alvin J. Siteman Cancer Center, Washington University, St. Louis, Missouri; and. 5. Department of Cell Biology and Physiology, Washington University, St. Louis, Missouri.
Abstract
Therapies targeting reductive/oxidative (redox) metabolism hold potential in cancers resistant to chemotherapy and radiation. A redox imaging marker would help identify cancers susceptible to redox-directed therapies. Copper(II)-diacetyl-bis(4-methylthiosemicarbazonato) (Cu-ATSM) is a PET tracer developed for hypoxia imaging that could potentially be used for this purpose. We aimed to demonstrate that Cu-ATSM signal is dependent on cellular redox state, irrespective of hypoxia. Methods: We investigated the relationship between 64Cu-ATSM signal and redox state in human cervical and colon cancer cells. We altered redox state using drug strategies and single-gene mutations in isocitrate dehydrogenases (IDH1/2). Concentrations of reducing molecules were determined by spectrophotometry and liquid chromatography-mass spectrometry and compared with 64Cu-ATSM signal in vitro. Mouse models of cervical cancer were used to evaluate the relationship between 64Cu-ATSM signal and levels of reducing molecules in vivo, as well as to evaluate the change in 64Cu-ATSM signal after redox-active drug treatment. Results: A correlation exists between baseline 64Cu-ATSM signal and cellular concentration of glutathione, nicotinamide adenine dinucleotide phosphate (NADPH), and nicotinamide adenine dinucleotide (NADH). Altering NADH and NADPH metabolism using drug strategies and IDH1 mutations resulted in significant changes in 64Cu-ATSM signal under normoxic conditions. Hypoxia likewise changed 64Cu-ATSM signal, but treatment of hypoxic cells with redox-active drugs resulted in a more dramatic change than hypoxia alone. A significant difference in NADPH was seen between cervical tumor orthotopic implants in vivo, without a corresponding difference in 64Cu-ATSM signal. After treatment with β-lapachone, there was a change in 64Cu-ATSM signal in xenograft tumors smaller than 50 mg but not in larger tumors. Conclusion: 64Cu-ATSM signal reflects redox state, and altering redox state impacts 64Cu-ATSM metabolism. Our animal data suggest there are other modulating factors in vivo. These findings have implications for the use of 64Cu-ATSM as a predictive marker for redox therapies, though further in vivo work is needed.
Therapies targeting reductive/oxidative (redox) metabolism hold potential in cancers resistant to chemotherapy and radiation. A redox imaging marker would help identify cancers susceptible to redox-directed therapies. Copper(II)-diacetyl-bis(4-methylthiosemicarbazonato) (Cu-ATSM) is a PET tracer developed for hypoxia imaging that could potentially be used for this purpose. We aimed to demonstrate that Cu-ATSM signal is dependent on cellular redox state, irrespective of hypoxia. Methods: We investigated the relationship between 64Cu-ATSM signal and redox state in human cervical and colon cancer cells. We altered redox state using drug strategies and single-gene mutations in isocitrate dehydrogenases (IDH1/2). Concentrations of reducing molecules were determined by spectrophotometry and liquid chromatography-mass spectrometry and compared with 64Cu-ATSM signal in vitro. Mouse models of cervical cancer were used to evaluate the relationship between 64Cu-ATSM signal and levels of reducing molecules in vivo, as well as to evaluate the change in 64Cu-ATSM signal after redox-active drug treatment. Results: A correlation exists between baseline 64Cu-ATSM signal and cellular concentration of glutathione, nicotinamide adenine dinucleotide phosphate (NADPH), and nicotinamide adenine dinucleotide (NADH). Altering NADH and NADPH metabolism using drug strategies and IDH1 mutations resulted in significant changes in 64Cu-ATSM signal under normoxic conditions. Hypoxia likewise changed 64Cu-ATSM signal, but treatment of hypoxic cells with redox-active drugs resulted in a more dramatic change than hypoxia alone. A significant difference in NADPH was seen between cervical tumor orthotopic implants in vivo, without a corresponding difference in 64Cu-ATSM signal. After treatment with β-lapachone, there was a change in 64Cu-ATSM signal in xenograft tumors smaller than 50 mg but not in larger tumors. Conclusion: 64Cu-ATSM signal reflects redox state, and altering redox state impacts 64Cu-ATSM metabolism. Our animal data suggest there are other modulating factors in vivo. These findings have implications for the use of 64Cu-ATSM as a predictive marker for redox therapies, though further in vivo work is needed.
Authors: Katherine Ann Price; Peter J Crouch; Irene Volitakis; Brett M Paterson; SinChun Lim; Paul S Donnelly; Anthony R White Journal: Inorg Chem Date: 2011-09-01 Impact factor: 5.165
Authors: Zachary T Schafer; Alexandra R Grassian; Loling Song; Zhenyang Jiang; Zachary Gerhart-Hines; Hanna Y Irie; Sizhen Gao; Pere Puigserver; Joan S Brugge Journal: Nature Date: 2009-08-19 Impact factor: 49.962
Authors: Farrokh Dehdashti; Perry W Grigsby; Jason S Lewis; Richard Laforest; Barry A Siegel; Michael J Welch Journal: J Nucl Med Date: 2008-01-16 Impact factor: 10.057
Authors: Susan J Gelman; Fuad Naser; Nathaniel G Mahieu; Lisa D McKenzie; Gavin P Dunn; Milan G Chheda; Gary J Patti Journal: Cell Rep Date: 2018-01-09 Impact factor: 9.423
Authors: Arya Sobhakumari; Laurie Love-Homan; Elise V M Fletcher; Sean M Martin; Arlene D Parsons; Douglas R Spitz; C Michael Knudson; Andrean L Simons Journal: PLoS One Date: 2012-10-31 Impact factor: 3.240
Authors: Xiumei Huang; Edward A Motea; Zachary R Moore; Jun Yao; Ying Dong; Gaurab Chakrabarti; Jessica A Kilgore; Molly A Silvers; Praveen L Patidar; Agnieszka Cholka; Farjana Fattah; Yoonjeong Cha; Glenda G Anderson; Rebecca Kusko; Michael Peyton; Jingsheng Yan; Xian-Jin Xie; Venetia Sarode; Noelle S Williams; John D Minna; Muhammad Beg; David E Gerber; Erik A Bey; David A Boothman Journal: Cancer Cell Date: 2016-12-12 Impact factor: 38.585